Appendix 2. Sensitivity analysis additionally adjusted for diabetes, hypertension and hypercholesterolemia: Association of risk factors with hazard of atrial fibrillation in patients who received allopurinol with no baseline atrial fibrillation before the index date of allopurinol episode

	Univariate		Multivariable-adjusted (model1)		Multivariable-adjusted (model2)	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (in years)						
65 - <75	Ref		Ref		Ref	
75 - <85	**1.47 (1.31,1.66)**	**<0.0001**	**1.51 (1.34, 1.70)**	**<0.0001**	**1.50 (1.33, 1.70)**	**<0.0001**
≥85	**2.12 (1.83,2.46)**	**<0.0001**	**2.20 (1.89, 2.57)**	**<0.0001**	**2.20 (1.89, 2.57)**	**<0.0001**
Gender						
Male	Ref		Ref		Ref	
Female	1.04 (0.93, 1.15)	0.50	0.93 (0.83, 1.04)	0.19	0.93 (0.83, 1.04)	0.18
Race						
White	Ref		Ref		Ref	
Black	**0.83 (0.70, 0.97)**	**0.02**	**0.80 (0.68, 0.94)**	**0.008**	**0.80 (0.68, 0.94)**	**0.006**
Other	**0.69 (0.58, 0.83)**	**<0.0001**	**0.64 (0.54, 0.77)**	**<0.0001**	**0.64 (0.53, 0.76)**	**<0.0001**
Diabetes	**1.24 (1.12, 1.38)**	**<0.0001**	**1.35 (1.21, 1.51)**	**<0.0001**	**1.35 (1.21, 1.51)**	**<0.0001**
Hypertension	1.21 (0.97, 1.51)	0.08	1.18 (0.94, 1.47)	0.16	1.18 (0.94, 1.48)	0.15
Hypercholesterolemia	0.90 (0.80, 1.02)	0.09	**0.87 (0.77, 0.99)**	**0.0332**	**0.87 (0.77, 0.99)**	**0.03**
Statins	0.95 (0.72, 1.24)	0.69	0.88 (0.66, 1.17)	0.38	0.88 (0.66, 1.17)	0.37
Beta blockers	**1.58 (1.22, 2.05)**	**0.0005**	**1.63 (1.24, 2.14)**	**0.0004**	**1.63 (1.24, 2.14)**	**0.0004**
Diuretics	1.09 (0.85, 1.40)	0.51	0.98 (0.75, 1.29)	0.90	0.98 (0.75, 1.29)	0.90
ACE inhibitor	0.99 (0.72,1.36)	0.95	0.94 (0.68,1.31)	0.72	0.94 (0.68,1.31)	0.72
Allopurinol	**0.86 (0.77, 0.97)**	**0.01**	**0.83 (0.74, 0.93)**	**0.002**	-	-
Allopurinol duration*						
0 days	Ref		-	-	Ref	
1-180 days	0.94 (0.80,1.11)	0.46	-	-	0.92 (0.78, 1.09)	0.33
181 days -2 years	0.90 (0.77,1.04)	0.16	-	-	**0.85 (0.73, 0.99)**	**0.04**
> 2 years	**0.68 (0.54, 0.65)**	**0.0009**	-	-	**0.65 (0.52, 0.81)**	**0.0002**

Model 1 = Allopurinol Use+ age + race + gender + Diabetes + hypertension + Hypercholesterolemia + beta blockers + diuretics + Ace inhibitors + Statins
Model 2 = Allopurinol duration + age + race + gender + Diabetes + hypertension + Hypercholesterolemia + beta blockers + diuretics Ace inhibitors + Statins